Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

49.71USD
20 Nov 2017
Change (% chg)

$1.19 (+2.45%)
Prev Close
$48.52
Open
$49.89
Day's High
$50.60
Day's Low
$48.20
Volume
131,676
Avg. Vol
72,231
52-wk High
$50.89
52-wk Low
$25.92

Select another date:

BRIEF-Enanta Pharma Q4 earnings per share $1.86

* Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305

BRIEF-Enanta Pharmaceuticals announces new data presentations on EDP-305

* Enanta Pharmaceuticals announces new data presentations on EDP-305, an FXR agonist for NASH and PBC, at The Liver Meeting 2017

BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c

* Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c

BRIEF-Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

* Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

BRIEF-Enanta pharmaceuticals Q3 loss per share $0.44

* Enanta pharmaceuticals reports financial results for its fiscal third quarter ended june 30, 2017

BRIEF-Enanta Pharmaceuticals announces new data on EDP-938

* Phase 1 clinical study for RSV expected to begin in fourth calendar quarter of 2017

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

Select another date: